0.46
+1.56%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Humacyte
From its filings with the US Securities and Exchange Commission
Humacyte is based in Durham, North Carolina and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HUMA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $2.0m and a net loss of $40.8m. At that date it held total assets of $116.4m and shareholders' equity of $3.1m.
Humacyte, Inc. is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, and in the first quarter of 2025 commenced the United States commercial launch of our first FDA-approved product. We are pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. We believe our regenerative medicine technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. We are leveraging our novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
We are initially using our proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels, or ATEVs. On December 19, 2024, the FDA granted full approval for the ATEV under the brand name Symvess® for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. Our ATEVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection.
Quoted from its 10-K, filed 27 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Sept 2020
- Employees
- 184
- Website
- humacyte.com ↗
- Head office
- 2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, 27713
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Kathleen SebeliusIndependent Chairman of the Board$356,000
- Dr. Laura NiklasonPresident, Chief Executive Officer, Director$905,436
- Mr. Dale SanderChief Financial Officer, Chief Corporate Development Officer, Treasurer, since 2021$704,189
- Dr. Heather PrichardChief Operating Officer$653,205
- Dr. Yang CaoChief Regulatory Officer
- Dr. Shamik ParikhChief Medical Officer$1.5m
- Mr. William ScheesseleChief Commercial Officer
- Mr. Brady DouganDirector$331,000
- Dr. John BamforthIndependent Director$449,247
- Dr. Emery BrownIndependent Director$331,000
- Mr. Michael ConstantinoIndependent Director$338,500
- Gen. C. Bruce GreenIndependent Director$331,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 36
- Environment
- 34
- Social
- 35
- Governance
- 39
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is engaged in developing off-the-shelf, universally implantable bioengineered human tissues.
- Headquartered in Durham, North Carolina with 184 employees.
- IPO occurred on 2020-09-22.
Weaknesses
- Source description states 164 employees, conflicting with provided 184 employees.
- Source description mentions 'HAV cabinet' which is not a standard term.
- Source description contains unverified claims about market targeting.
Opportunities
- Potential to expand into vascular repair, reconstruction, and replacement markets.
- Opportunity to develop HAVs for pediatric heart surgery and cellular therapies.
- Growth potential in treating Type 1 diabetes through pancreatic islet cell transplantation.
Threats
- Unverified claims in source description may lead to misinformation.
- Conflicting employee count may indicate internal reporting issues.
- Market targeting claims lack verification and could be inaccurate.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.